Teva Pharmaceutical Industries (TEVA) Non-Current Deferred Tax Liability (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $289.0 million in Q2 2026.

• Quarterly Non-Current Deferred Tax Liability fell 34.32% year-over-year to $289.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $289.0 million (down 34.32% YoY) and the FY2025 annual result came in at $296.0 million, down 38.72% from the prior year.
• Non-Current Deferred Tax Liability climbed to $289.0 million in Q2 2026, from $273.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $666.0 million in Q1 2022 to a low of $273.0 million in Q1 2026.
• A 5-year average of $488.0 million and a median of $533.0 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability plunged 44.73% — and 2023, when it rose 10.58%.
• Tracing TEVA's Non-Current Deferred Tax Liability over 5 years: stood at $548.0 million in 2022, then grew by 10.58% to $606.0 million in 2023, then retreated by 20.3% to $483.0 million in 2024, then sank by 38.72% to $296.0 million in 2025, then decreased by 2.36% to $289.0 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $289.0 million (Q2 2026), $273.0 million (Q1 2026), and $296.0 million (Q4 2025), per Business Quant data.